Aberrant activation of Notch signaling contributes to the pathogenesis of several different types of cancer, and Notch pathway inhibitors may have significant therapeutic potential. Using a unique cellbased assay system, we isolated twelve compounds, including one new natural product from Garcinia speciosa, that inhibit the Notch signaling pathway. HES1 and HES5 are target genes of the Notch cascade, and compound 2, referred to as cowanin, decreased the protein levels of HES1 and HES5 in assay cells. Furthermore, cowanin (2) showed potent cytotoxicity against human leukemic HPB-ALL cells. The Notch signaling inhibitory activity of cowanin (2) is linked to the increased degradation of nicastrin, which is one of the components of the γ-secretase complex. To the best of our knowledge, this is the first example of a compound with Notch pathway inhibitory activity mediated by nicastrin degradation.
Notch signaling plays a pivotal role in the regulation of many fundamental cellular processes, including proliferation and stem cell maintenance. It also influences cell differentiation decisions at various stages during embryonic and adult development 1, 2 . It is apparent that an important direct output of Notch activity is the upregulation of basic helix-loop-helix (bHLH) transcriptional repressors such as the hairy and enhancer of split 1 (HES1), HES5 and HES related (HESR/HEY) family genes. Notch signaling has an important role in the regulation of neural stem cell differentiation 3, 4 , and the differentiation of neural stem cells into neurons can be inhibited by Notch signaling. In direct contrast, the Notch pathway also promotes astrocyte differentiation from glial progenitors derived from neural stem cells. Aberrant upregulation of Notch signaling is oncogenic in multiple hematologic and solid malignancies [5] [6] [7] . For example, activating mutations of NOTCH1, a transmembrane receptor that regulates normal T cell development, drives the development of human T-cell acute lymphoblastic leukemia (T-ALL) 8 . Notch has been proven to be an oncoprotein in melanocytes 9 , prostate 10 , and breast 11 cancer cells, providing significant impetus for the development of clinically effective Notch pathway inhibitors 12 .
Signal transduction from Notch receptors is shown in Fig. 1 . Notch signaling is activated by interaction between the ligand-expressing cell and the signal-receiving cell. The binding of Jagged or Delta ligand proteins to the Notch receptor induces a conformational change, exposing the S2 cleavage site in the Notch receptor to the metalloproteinase containing protein, ADAM/TACE. Following S2 cleavage, the subsequent S3 cleavage is mediated by γ-secretase, which is a multi-subunit complex composed of presenilin 1 (PS1), nicastrin, presenilin enhancer 2 (PEN-2) and anterior pharynx-defective 1 (APH-1). The S3 cleavage results in the release of the Notch intracellular domain (NICD), which translocates to the nucleus and forms a heterotrimer with mastermind-like protein (MAML) and DNA binding protein recombination signal binding protein for immunoglobulin kappa J region (RBP-J) to initiate transcription of target genes.
Various Notch inhibitors have been reported including γ-secretase inhibitors, DAPT (N-[N-(3,5-difluorop henacetyl)-L-alanyl]-S-phenylglycine t-butyl ester) 13 , RO4929097 14 , MK-0752 15 and PF0384014 16 . SHAM1, a MAML1-derived peptide that inhibits the binding of full-length MAML1 to NICD1-RBP-J, was also reported as a potent Notch signaling inhibitor 17 . The natural products, curcumin 18 and genistein 19 , downregulate Notch1. Butein was also reported as a potent inhibitor 20 . A peptide-based protein knockdown system was also developed for degradation of Notch1 21 . Efforts have been taken to develop Notch signaling inhibitors as agents with clinically used chemotherapeutics to treat cancer 12 . However, the development of Notch inhibitors from natural products has been limited despite the increasing realization that natural products are a valuable repository of The addition of Dox inactivates TetR to initiate expression of Notch1(1704-2531), which is then cleaved by endogenous γ-secretase to form NICD. NICD then translocates to the nucleus and forms a heterotrimer with RBP-J and MAML that binds to a 12× RBP-J binding site to drive luciferase expression. Luciferase activity was detected as Notch signaling pathway activity. Dox: doxycycline, TetR: tetracycline repressor, Luc.: luciferase. 32 , compound 12 was presumed to have the furan-2-yl moiety with a 1-methylethenyl portion. The 13 C-NMR spectrum revealed 24 carbons. The position of the prenyl side chain at C-8 was confirmed by the HMBC correlation between the methylene proton at δ H 4.09 (d, 2H, J = 5.8 Hz, H-1′′) with C-8 (δ C 137.1), C-7 (δ C 142.5) and C-8a (δ C 111.7), while the position of the methoxy group at C-7 was determined by the correlation of the methoxy proton at δ H 3.79 (s, 3H) with C-7 (δ C 142.5) (Fig. 4) . The position of a 1-methylethenyl group was determined by the HMBC correlations between methyl proton at δ H 1.69 (s, 3H, H-5′) and C-2′.
Next, we investigated the Notch signal inhibitory activity of the twelve compounds (Fig. 5 ). Compounds 1, 2, 3 and 7 showed potent inhibitory activity with IC 50 values of less than 10 μM (8.0, 2.4, 7.3 and 7.5 μM, respectively). Compounds 4, 9, 10 and 11 had moderate activity with IC 50 values of 10.5, 19.6, 15.0 and 11.7 μM, respectively. The remaining compounds, 5, 6, 8 and 12, had weak activity or were inactive. The Structure-Activity Relationship (SAR) of isolated Notch inhibitors indicated that two prenyl moieties at C-2 and C-8 strengthened activity. From the comparison of the activities of compounds 1 and 10, the OH group at the C-6 position was preferred over the methoxy group. The methoxy group at the C-7 position seemed to be preferred for activity. In addition, the ring portions at C-2 and C-3 weakened activity based on comparisons of 1 with 9 or 12, and 2 with 11. We focused on compound 2, referred to as cowanin, which had the strongest inhibitory activity. The expression of the Notch signaling target proteins, HES1 and HES5, was reduced by the addition of cowanin (2) to the assay cells (Fig. 6A ,C,D). NICD was reduced dose dependently ( Fig. 6B,F) , while the expression of Notch1(1704-2531) was increased ( Fig. 6B,E ). This result indicated that cowanin (2) might affect the activity of the γ-secretase complex.
To investigate the effect of cowanin (2) on cancer cells, the cytotoxicity of the compound on the T-ALL cell line, HPB-ALL, was evaluated (Fig. 7A ). Cowanin (2) reduced the viability of HPB-ALL cells at 10 μM, while the viability of normal human embryonic kidney 293 cells was not affected, although cytotoxicity was detected at 20 μM. Cowanin (2) showed stronger cytotoxicity than that of the known γ-secretase inhibitor DAPT (Fig. 7A) . Although IC 50 of Notch signal inhibitory activity of DAPT in our luciferase assay system was 0.12 μM, cowanin (2) showed high efficient cytotoxicity against cancer cells HPB-ALL than that of DAPT (IC 50 >20 μM) (Fig. 7A) . The IC 50 values of cowanin (2) were 7.5 μM (HPB-ALL cells) and 15.1 μM (293 cells) (Fig. 7B ). This difference of cytotoxicity between cancer cells and normal cells is also attractive. The expression of NICD and HES1 was reduced in HPB-ALL cells at 10 μM significantly ( Fig. 7C-E) .
The effects of cowanin (2) on the expression of components of the γ-secretase complex (Fig. 8A) , nicastrin ( Fig. 8B) , APH-1, PS1 and PEN-2 ( Fig. 8C) were evaluated to address the mechanisms by which cowanin (2) inhibits γ-secretase activity. It was known that the activity site exists in PS1 but the complexation of these four proteins is important for activity 33 . Although cowanin (2) didn't affect the expression of APH-1, PS1 and PEN-2, nicastrin levels were reduced (Fig. 8B) . To address the possibility that cowanin (2) accelerates the degradation of nicastrin, a proteasome inhibitor, MG132, was co-incubated with cowanin (2) (Fig. 8D-F) . We confirmed that the cell viability was 98% under 12 h treatment of cowanin (2) (15 μM). When MG132 (5 μM) was added to HPB-ALL cells with cowanin (2) (15 μM), the decrease in nicastrin expression was not so marked. These data indicated that the mechanism of Notch inhibition by cowanin (2) was acceleration of nicastrin degradation. As Fig. 8F showed, cowanin (2) decreased immature nicastrin stronger than mature nicastrin. Nicastrin was known to be matured by glycosylation of a large extracellular domain. And PS1 interacts preferentially with mature nicastrin 34 . Therefore, hydrophobic compound, cowanin (2), might prefer to bind immature extracellular domain without glycans. By cowanin (2) binding, PS1 binding to nicastrin might be reduced. That might cause to increase the amount of unstable free nicastrin, then degradation of nicastrin might be accelerated. 
Conclusion
In conclusion, we report the isolation of twelve compounds, including one new natural product, using our cell-based assay for Notch signal inhibitors. Cowanin (2) was shown to inhibit γ-secretase activity by reducing nicastrin levels, which was the result of the acceleration of nicastrin degradation. To the best of our knowledge, this is the first example of a compound that accelerates nicastrin degradation and shows Notch inhibitory activity.
Methods
General Experimental Procedures. Optical rotations were recorded on a JASCO P-1020 polarimeter.
NMR spectra were recorded on JEOL ECP600 and ECZ600 spectrometers in a deuterated solvent whose chemical shift was taken as an internal standard. ESI-MS were obtained on a JEOL JMS-T100LP. Silica gel 60 N (Kanto Chemical Co., Inc., Tokyo, Japan), Chromatorex ODS and Chromatorex PSQ100B (Fuji Silysia Chemical Ltd., Kasugai, Japan) were used for column chromatography. Luna Phenyl-Hexyl (ϕ 10 × 250 mm) (Phenomenex Torrance, CA) was used for Preparative HPLC. Nano Drop 2000 spectrophotometer (Thermo Fisher Scientific Inc., Waltham, USA) was used for protein concentrations measurement. MeOH-H 2 O = 85:15, flow rate 2.0 mL/min) to afford compound 8 (1.4 mg, t R 31.6 min) and compound 1 (0.7 mg, t R 36.8 min). Fr. 7D (31.2 mg) was subjected to HPLC (Luna Phenyl-Hexyl; MeOH-H 2 O = 90:10, flow rate 2.0 mL/min) to give the fractions 9A to 9F and gave compound 2 (0.5 mg, t R 31.6 min) and compound 7 (2.4 mg, t R 34.0 min). Fr. 9B was further separated by HPLC (Luna Phenyl-Hexyl; MeOH-H 2 O = 83:17, flow rate 2.0 mL/min) to afford compound 9 (1.2 mg, t R 99.0 min) and compound 10 (1.6 mg, t R 107.0 min). Fr. 2B (1634.5 mg) was separated by ODS column chromatography (ϕ 30 × 300 mm; H 2 O-MeOH = 15:85-0:1, and 0.1% TFA in MeOH) to give the fractions 3A to 3G. Fr. 3C (49.8 mg) was subjected to HPLC (Luna Phenyl-Hexyl; MeOH-H 2 O = 87:13, flow rate 2.0 mL/min) to afford compound 5 ( Cell culture. HPB-ALL cells were purchased from RIKEN BRC. Assay cells (LS174T Notch cells) and HEK293 cells were incubated in Dulbecco's modified Eagle medium (DMEM) (Wako, Osaka, Japan) with 10% fetal bovine serum (FBS; BioWest, Nuaillé, France; Sigma-Aldrich Co. LLC., St. Louis, USA), Streptomycin (100 μg/mL) and Penicillin (100 unit/mL) (Sigma-Aldrich Co. LLC., St. Louis, USA). HPB-ALL cells were incubated in RPMI-1640 (Wako, Osaka, Japan) with 10% FBS, Streptomycin (100 μg/mL) and Penicillin (100 unit/mL). Cultures were maintained in a incubator at 37 °C in 5% CO 2 and 95% air.
Cytotoxicity test. HEK293 cells (1 × 10
4 cells per well) were incubated in 96-well black plates in 100 μL of DMEM medium containing 10% FBS, Streptomycin (100 μg/mL) and Penicillin (100 unit/mL) at 37 °C for 24 h. The medium was exchanged to fresh medium with different concentrations of compound and cells were incubated for 72 h. Fluorometric microculture assay (FMCA) was used for determination of cell proliferation using a fluorescence plate reader (Thermo Fisher Scientific Inc., Waltham, USA).
HPB-ALL cells (1 × 10 4 cells per well) were incubated in 96-well black plates in 100 μL of RPMI-1640 medium with 10% FBS, Streptomycin (100 μg/mL) and Penicillin (100 unit/mL). Media also contained different concentrations of compound. Cells were incubated at 37 °C for 72 h. After incubation, AlamarBlue (00-025, DAL1025; Thermo Fisher Scientific Inc., Waltham, USA) was added 10 μL per well. After incubation for 4 h, using a fluorescence plate reader (Thermo Fisher Scientific Inc., Waltham, USA), fluorescence was measured and cell viability was determined. Western blotting analysis. Cells (LS174T Notch cells; 1 × 10 6 cells per dish) were incubated in a 6 cm dish for 12 h at 37 °C in 5 mL of DMEM medium with 10% FBS, Streptomycin (100 μg/mL) and Penicillin (100 unit/ mL). Before another 12 h incubation, 50 ng/mL of doxycycline was added into each dish. Then, medium was changed to fresh medium with each compound. After 12 h incubation, cells were washed with PBS (500 μL) twice and then cells were collected by scraping. Using lysis buffer (20 mM Tris-HCl pH 7.4, 150 mM NaCl, 0.5% sodium deoxycholate, 10 mM EDTA, 1 mM sodium orthovanadate, and 0.1 mM NaF) containing a 1% proteasome inhibiotor cocktail (Nacalai Tesque, Tokyo, Japan), protein lysate was prepared. Protein lysates were separated by a 7.5%, 10%, 12.5% and 15% SDS-PAGE electrophoresis. Proteins were then transferred to a PVDF membrane (Bio-Rad Laboratories, Inc. Hercules, USA) electrophoretically. The membrane was incubated for 1 h with TBST (10 mM Tris-HCl pH 7.4, 100 mM NaCl and 0.1% Tween 20) containing 5% skimmed milk. Then, the membrane was mixed at 4 °C for 12 h with primary antibodies anti-β-actin (A2228; dilution 1:4000, Sigma-Aldrich, Co. LLC., St. Louis, USA), anti-cleaved Notch1 (Val1744) (2421, 4147; dilution 1:1000, Cell Signaling Technology, Inc., Danvers, USA), anti-FLAG (F7425; dilution 1:1000, Sigma-Aldrich, Co. LLC., St. Louis, USA), anti-HES1 (sc-13844; dilution 1:1000, Santa Cruz Biotechnology, Inc., Dallas, USA), anti-HES5 (ab25374; dilution 1:250, ab194111; dilution 1:1000, Abcam plc., Cambridge, UK), anti-aph1a (ab62821; dilution 1:1000, Abcam plc., Cambridge, UK), anti-nicastrin (5665; dilution 1:1000, Cell Signaling Technology, Inc., Danvers, USA), anti-presenilin1 (5643; dilution 1:1000, Cell Signaling Technology, Inc., Danvers, USA) or anti-pen2 (8598; dilution 1:1000, Cell Signaling Technology, Inc., Danvers, USA). Then, the TBST wash of membrane was performed and membrane was mixed at room temperature for 1 h with secondary antibodies either anti-rabbit IgG (111-035-144; dilution 1:4000, Jackson Immuno Research Inc., West Grove, USA), anti-rabbit IgG (7074; dilution 1:4000, Cell Signaling Technology, Inc., Danvers, USA), anti-goat IgG (705-035-003; dilution 1:10000, Jackson Immuno Research Inc., West Grove, USA) or anti-mouse IgG (NA931; dilution 1:4000, GE Healthcare Japan, Tokyo, Japan). After TBST was of membrane, detection of immunocomplexed bands were performed by an ECL Advance Western (RPN2135; GE Healthcare Japan, Tokyo, Japan), ECL Select Western (RPN2235; GE Healthcare Japan, Tokyo, Japan) or an Immobilon Western (WBKLS0100; Merck Millipore Co., Darmstadt, Germany) detection system.
HPB-ALL cells were incubated in a 6 cm dish in 5 mL of RPMI-1640 medium with 10% FBS, Streptomycin (100 μg/mL) and Penicillin (100 unit/mL) at 5 × 10 5 cells per dish (1 × 10 6 cells per dish, when treatment with MG132). Media also contained different concentrations of compound. Cells were incubated at 37 °C for 72 h (12 h, when treatment with MG132). After incubation, cells were centrifuged and collected, and then washed with 500 μL of PBS twice. To prepare cell lysate and confirm protein expression levels, the same method as described above was used. 
